

31 Surveying the Literature on Implementation Determinants and Strategies for HIV Structural

32 Interventions: A Systematic Review Protocol

33 **Abstract**

34 **Background:** Despite improvements in HIV prevention, treatment, and surveillance, vast
35 disparities remain in access, uptake, and adherence of evidence-based interventions. These
36 disparities are most pronounced among racially, sexually, and gender minoritized populations, as
37 well as among those living in poverty and/or who use injectable drugs. Structural interventions,
38 or interventions that target social and structural determinants of health like housing,
39 transportation, or income, are needed to increase access to, use of, and adherence to HIV EBIs to
40 advance the aims of the national Ending the HIV Epidemic initiative. However, it is unclear to
41 what extent barriers and facilitators of structural interventions have been identified in the U.S.
42 and what implementation strategies and adjunctive interventions have been developed to enhance
43 their delivery.

44 **Methods:** To identify what implementation determinants, implementation strategies, and
45 adjunctive interventions have been identified for HIV structural interventions, we carried out a
46 broad database search between May and July 2024, identifying a total of 8,098 articles. We will
47 use a multi-step process to identify articles to include in the systematic review. We will use
48 natural language processing to identify articles for exclusion, followed by manual text review
49 and extraction using COVIDENCE software. Literature on determinants will be coded according
50 to the Consolidated Framework for Implementation Research. Implementation strategies and
51 adjunctive interventions will be coded according to the Expert Recommendations for
52 Implementing Change, the Theoretical Domains Framework, and COM-B. We will descriptively
53 analyze determinants, implementation strategies, and adjunctive interventions, use natural
54 language processing for thematic analysis of determinants, implementation strategies, and

55 adjunctive interventions, and provide narrative description of implementation strategies and

56 adjunctive interventions.

57 **Discussion:** This systematic review will identify key barriers and facilitators for HIV structural

58 intervention implementation strategies, including multi-level approaches to address disparities

59 among marginalized populations. Findings will provide insights for advancing equitable, scalable

60 interventions to support the goals of the Ending the HIV Epidemic initiative.

61 **Systematic review registration:** CRD42024554315

62

63 **Keywords:** Systematic Review; Protocol Paper; HIV/AIDS; Structural Intervention;

64 Implementation Science

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79 **Background**

80 The HIV epidemic disproportionately impacts minoritized populations, underscoring the need
81 to examine the social and structural determinants of health (SSDOH) that contribute to these
82 inequities (1,2). SSDOH include the “upstream” or structural factors like public policy,
83 economic context, social and cultural values, and political ideology that produce or give shape to
84 social determinants of health (3). SSDOH, thus, also include the more “mid-stream” or social
85 factors, often referred to as the conditions where individuals work, live, grow, and play, that
86 shape a populations’ health before individuals step foot in a clinic (3). The federal government
87 has identified “key populations” that are disproportionately affected by the HIV epidemic due, in
88 part, to SSDOH: cisgender gay, bisexual, and other men who have sex with men of all races and
89 ethnicities (MSM); Black women people who inject drugs (PWID); youth aged 13 to 24 years;
90 and transgender women (4). Despite improvements in overall HIV incidence due to the
91 development and implementation of numerous evidence-based interventions (EBIs), trends in the
92 United States highlight the disparities between these groups and the general population (5). For
93 example, between 2018 and 2022, new HIV diagnoses in Black, Indigenous, Hispanic/Latine,
94 and Native Hawaiian or Pacific Islander populations increased, but decreased or stabilized in
95 Asian and White populations, respectively (5). SSDOH such as racism, access to care, economic
96 status, and social stigma can all contribute to discrepancies in HIV diagnosis, treatment, and
97 prevention rates (6).

98 Pre-exposure prophylaxis (PrEP), an oral pill or bimonthly injection that significantly reduces
99 the risk of acquiring HIV (7–9), is a critical tool in HIV prevention, but disparities in access and
100 uptake present significant challenges. For example, PrEP uptake has been slow among Black and
101 Latine individuals, particularly Black females and Latino males (10,11). Barriers such as stigma,

102 medical mistrust, and structural racism contribute to the inequitable distribution of PrEP, limiting
103 its full potential in reducing HIV incidence (12).

104 Treatment as Prevention, another critical innovation, involves the suppression of individuals'
105 HIV viral load through consistent antiretroviral therapy (ART) adherence and has emerged as a
106 highly effective strategy in preventing the transmission of HIV through sex, syringe sharing, and
107 vertical (mother-to-child) transmission (13–18). However, barriers to access to care and to ART
108 adherence remain prevalent among key populations, including housing instability, lack of access
109 to transportation, substance use, which each, without further patient support, contribute to
110 patients missing a greater number of clinic appointments (19).

111 Achieving the goals of the Ending the HIV Epidemic in the US (EHE) Initiative to reduce
112 HIV incidence and improve health equity necessitates the implementation of structural
113 interventions (20). Structural interventions attempt to make changes to the performance and
114 creation of public health initiatives (21). These interventions target the structural factors of a
115 public health initiative that can influence the target population's behavior. The structural factors
116 (or determinants) influencing health behaviors can include social inequalities, economic factors,
117 cultural influences, policies, and physical structures (21). Structural interventions have been used
118 as a preventative strategy to target the structural variables that impact behavior and risk of
119 obtaining HIV. For example, the provision of housing as an intervention has been found to
120 reduce engagement in sexual and substance use behaviors that may increase the likelihood of
121 acquiring HIV, as well as to increase access and adherence to ART (22).

122 While a growing body of literature has attended to developing and piloting structural
123 interventions, there has been less attention to their implementation within the U.S.
124 Implementation science has identified a persistent gap between the development, piloting, and
125 trialing of an EBI and its eventual implementation (referred to as the implementation gap (23)).

126 Thus, it is necessary for researchers to identify the implementation determinants, or barriers and
127 facilitators, of structural interventions and the implementation strategies or processes, methods,
128 policies, and programs to increase the reach, effectiveness, adoption, implementation, and
129 sustainability of the interventions (24–27). Structural interventions will also likely require the
130 identification and development of adjunctive interventions, or methods to increase patient
131 uptake, access, and adherence to the intervention (28). Implementation science’s focus on swift
132 translation of research to practice is necessary to achieve the goals of the EHE initiative (29).

133 Thus, we aim to carry out a systematic review to identify:

- 134 1. What implementation determinants, implementation strategies, and adjunctive
135 interventions have been identified as relevant to the adoption, acceptability,
136 feasibility, appropriateness, reach, cost, sustainability, and equitable delivery of
137 structural interventions for HIV EBIs?
- 138 2. What gaps are present in the literature regarding the implementation of structural
139 interventions for HIV EBIs?
- 140 3. How are or how may structural interventions be differentiated from implementation
141 strategies and adjunctive interventions?

142 **Methods**

143 *Search Strategy*

144 Between May and July 2024, a broad database search strategy (see **Supplemental File 1**) was
145 carried out to identify literature focused on implementation determinants, implementation
146 strategies, and adjunctive interventions for structural interventions for HIV EBIs along the HIV
147 prevention and care continua (30,31). The protocol for this search is registered with the
148 International Prospective Register of Systematic Reviews (PROSPERO ID: CRD42024554315).
149 A research librarian provided consultation on the search strategy and recommended additional

150 databases to search. The first author (az) searched Ovid MEDLINE [2000-2024], Embase
151 (Elsevier) [2000-2024], PsycINFO (EbscoHost) [2000-2024], Web of Science [2000-2024],
152 Sociological Abstracts [2000-2024], Google [All years], and ProQuest Congressional CRS
153 Reports and Miscellaneous Publications [2000-2024]. The second author (VAD) also identified
154 the primary sources from the CDC's compendium of evidence based structural interventions for
155 HIV to add to the initial search (32). From this, 8,098 articles were identified before duplication.
156 Using these articles, we will conduct a systematic review in two phases: 1) identifying
157 implementation determinants and 2) identifying implementation strategies and adjunctive
158 interventions. Both phases of the systematic review will be carried out in compliance with the
159 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA; see
160 **Supplemental File 2**).

161 *Screening and eligibility criteria*

162 We used a multi-step process to identify articles to include in the systematic review. Inclusion
163 criteria include: 1) a focus on HIV/AIDS; 2) 50% or more of the study sample is based in the
164 U.S.; 3) the study is an implementation or hybrid implementation-effectiveness study (33); 4) the
165 study contains original research with an original data sample; 5) behavioral or social science
166 (i.e., not basic science); 6) the study reports, explores, or tests at least one implementation
167 outcome (i.e., acceptability, feasibility, adoption, fidelity, implementation costs, reach,
168 sustainability (26,27)); and 7) that the intervention either (a) affects risks and/or behavioral
169 choices by changing something external to the individual and not under their control and/or (b)
170 targets social determinants of health.

171 Preliminary inclusion was determined using natural language processing (NLP) to analyze
172 titles and abstracts (N = 8,092) and classify articles for eligibility in our systematic review. NLP
173 was performed by author MH using R version 4.4.1 (34) and packages *quanteda* for quantitative

174 analysis of textual data (35), RWeka for machine learning algorithms for data mining (36), and
175 tidyverse (37), tidytext (38), broom (39), readr (40), stringr (41), and magrittr (42) for data
176 cleaning and manipulation. Five domains, with separate R scripts, were defined: 1) Domestic
177 Setting (i.e., not international or foreign); 2) Study Design; 3) Behavioral Science; 4) HIV/AIDS
178 Relevance; and 5) Structural Intervention. Using the quanteda package in R, each article was
179 assigned a label for inclusion, exclusion, further inspection required, or no label based on the
180 quantified presence of predetermined terms. 405 articles were assigned an ‘include’ label across
181 all five domain classifiers, and 4,285 articles contained at least one ‘further inspection’ label and
182 were not assigned an ‘exclude’ label across any classifier. Lastly, results were output into a table
183 indicating the classification of each article.

184 After computerized exclusion, articles identified for inclusion in the NLP were uploaded to
185 COVIDENCE for manual review (43). COVIDENCE will automatically identify duplicate
186 articles for exclusion. A team of trained investigators, including but not limited to a faculty
187 investigator with experience leading systematic reviews (az), a postdoctoral fellow (MP), and
188 two research staff with Bachelor-level training (VAD, SC), will conduct the manual review. The
189 research staff and postdoctoral fellow were trained by az to review articles until 90% reliability
190 was reached between their identification of articles to include and az’s identification of articles to
191 include. Manual review will begin with title and abstract review. The team of investigators will
192 screen each article’s title and abstract to identify whether to include or exclude each article based
193 on the same criteria as the NLP will use. Following, title and abstract review, we will conduct
194 full-text review of each article, once again screening each article to identify whether to include or
195 exclude each article based on the same criteria as the prior two steps. In both steps of manual
196 screening, each article will be reviewed by two investigators. In the case of disagreement, the
197 article will be re-reviewed by senior members of the team (az and NB) for consensus.

198 *Extraction*

199 Following the multi-step screening process, we will manage and extract data from articles
200 using COVIDENCE software. Extraction will include identification of high-level information
201 detailed in Table 1. This will include CDC-identified priority populations, which are based on
202 disparities in HIV prevalence and incidence in the U.S. Study type will be categorized as within-
203 site designs (e.g., post-design examination of healthcare processes), between-site designs (e.g.,
204 comparing a new implementation strategy to usual practice or comparing different
205 implementation strategies), within- and between-site designs (e.g., roll-out designs), non-
206 experimental designs (e.g., qualitative designs, surveys that aren't part of a larger trial),
207 configurational comparative methods (e.g., qualitative comparative analysis, coincidence
208 analysis), simulation study, or other type of design (44). Implementation outcomes, or “the
209 effects of deliberate and purposive actions to implement new treatments, practices, and services,”
210 will be categorized according to the oft-cited Proctor et al. (2011) framework for implementation
211 outcomes, which includes acceptability, adoption, appropriateness, costs, feasibility, fidelity,
212 penetration, and sustainability (26). In addition to other extraction variables, we will categorize
213 structural intervention types using a taxonomy developed by Sipe et al. (2017). These include
214 interventions aimed at increasing access to an HIV EBI, policy/procedure interventions, the use
215 of mass media to disseminate an intervention, interventions changing the physical structure
216 where an HIV EBI is delivered, capacity-building interventions, community mobilization as an
217 intervention, and interventions targeting SDOH (45). Extraction will be conducted by two
218 members of the investigative team (VAD, MP, SC) for each article. Consensus for any
219 discrepancies will be reviewed for final decision making by senior members of the team (az,
220 NB).

221 *Determinants Coding*

222 Following extraction, articles identified as assessing implementation determinants will be
223 uploaded to MaxQDA, a qualitative data analysis software, for coding (46). Determinants coding
224 will focus on barriers and facilitators to implementing the structural intervention, rather than
225 barriers and facilitators to implementing an HIV EBI. Determinants will be coded according to
226 valence (i.e., barrier, facilitator, both, neither) and structural intervention type. We will also code
227 the determinant level; that is, whether the determinant is an innovation determinant or an
228 implementation determinant. In comparison to implementation determinants, innovation
229 determinants are barriers or facilitators to patients or other recipients of an EBI access, using,
230 adhering to, or otherwise receiving the intervention (47). Finally, we will code determinants
231 using the domains and constructs of the Consolidated Framework for Implementation Research
232 (CFIR) 2.0 as codes (24,25). CFIR is the most widely-cited compendium (48,49) of
233 implementation determinants and includes five domains: 1) innovation characteristics (i.e.,
234 factors about the EBI itself that make it more or less difficult to be delivered); 2) outer setting
235 (i.e., contextual factors in the larger society or community); 3) inner setting (i.e., contextual
236 factors within the setting in which an EBI is delivered that make it more or less difficult to do
237 so); 4) individuals (i.e., whether individuals delivering an EBI have the capability, opportunity,
238 and motivation to do so); and 5) process (i.e., factors about the actual process of implementing
239 an EBI that hinder or facilitate delivery, such as engaging patients or adapting the EBI). The
240 investigative team (VAD, SC, MP) will be trained by a senior team member (az) in use of
241 MaxQDA and coding of determinants. We will continue training and practice coding until an
242 interrater reliability of at least $\kappa = .70$ is reached.

243 *Strategy and adjunctive intervention coding*

244 Following extraction, articles identified as assessing strategies (including implementation
245 strategies and adjunctive interventions) will be coded in Excel. Coding will be performed of

246 implementation strategies and adjunctive interventions for structural interventions, rather than
247 implementation strategies and adjunctive interventions for HIV EBIs. The investigative team
248 (VAD, SC, MP) will be trained by a senior team member (az) in coding of strategies. Each
249 article will be coded by two investigators who will meet to review their individual coding and
250 come to consensus on discrepancies. In the case that they cannot come to consensus, a senior
251 team member (NB) will be brought in to finalize consensus. Strategy coding will begin by
252 identifying whether the article is examining an implementation strategy or an adjunctive
253 intervention.

254 Implementation strategy coding will include 1) identification of the discrete strategies, their
255 names, their temporal order, and their definition/description; 2) differentiation of the structural
256 intervention and the implementation strategies (if possible); 3) coding of each discrete
257 implementation strategy to Expert Recommendations for Implementing Change (ERIC)
258 framework (50); 4) identification of the specific implementation outcomes each discrete strategy
259 is targeting; 5) identification of the effectiveness of the strategy based on quantitative evidence
260 of effectiveness in comparison to a control group, baseline, or other comparator; 6) whether the
261 investigators assess health disparities and/or health equity, with health disparities defined as
262 identifying a disparity and health equity defined as targeting disparities, including a priority
263 population, and/or having a community-based study design; 7) identification of the stage of
264 implementation research (i.e., are they developing, piloting, testing/trialing, and/or comparing
265 strategies); 7) study design (e.g., observational, within-site); 8) sample size; 9) whether the
266 investigators use a hybrid approach in the study design (i.e., hybrid implementation-effectiveness
267 approach (44)); 8) assessment of how well specified each discrete strategy is according to
268 recommendations by Proctor et al. on a 3-point scale, with each coder rating the level of
269 specification (0 = no details provided; 1 = very little detail; 2 = there is some detail about

270 components of the strategy but key details are left out; 3 = investigators clearly indicate the
271 components of the implementation strategy such that it could be replicated (51)); and 9) whether
272 the authors identified the specific determinants the strategy aims to target.

273 Adjunctive intervention coding will include 1) identification of the discrete components of the
274 adjunctive intervention (e.g., training, on-going supervision, audit and feedback); 2) description
275 of the adjunctive intervention components; 3) coding the adjunctive intervention components to
276 the Theoretical Domains Framework (TDF) and COM-B (52,53); 4) identification of the specific
277 outcomes each discrete component is targeting (i.e., intervention awareness, acceptability,
278 feasibility, uptake, adherence, costs, and maintenance, implementation strategy acceptability,
279 appropriateness, feasibility, and fidelity); 5) whether the investigators assess health disparities
280 and/or health equity, with health disparities defined as identifying a disparity and health equity
281 defined as targeting disparities, including a priority population, and/or having a community-
282 based study design; 6) identification of the effectiveness of the adjunctive intervention based on
283 quantitative evidence of effectiveness in comparison to a control group, baseline, or other
284 comparator; 7) identification of the stage of implementation research (i.e., are they developing,
285 piloting, testing/trialing, and/or comparing adjunctive interventions); 8) study design (e.g.,
286 observational, within-site); 9) sample size; 10) whether the investigators use a hybrid approach in
287 the study design (i.e., hybrid implementation-effectiveness approach); 11) assessment of how
288 well specified each discrete component of the adjunctive intervention is; 12) identification of
289 who the intervention is delivered to; 13) whether the investigators identify the recipient/patient-
290 level determinants the adjunctive intervention aims to target.

291 *Analysis*

292 **Determinants.** We will export data to Excel to tabulate the number of discrete determinants
293 by CFIR constructs. We will further stratify determinants by delivery setting, CDC priority

294 populations, study method, type of structural intervention (45), the particular HIV EBI the
295 structural intervention is targeting, and implementation outcomes associated with the
296 determinants. Due to the large amount of data potentially analyzed, we will use NLP to
297 thematically analyze determinants to provide narrative description of the types of determinants
298 identified across papers (54).

299 **Strategies and adjunctive interventions.** For implementation strategies and adjunctive
300 interventions, we will tabulate the number of discrete implementation strategies according to
301 ERIC strategies and the number of adjunctive intervention components according to TDF and
302 COM-B constructs. We will further stratify implementation strategies and adjunctive
303 interventions by study design, stage of research, type of structural intervention (45), the
304 particular HIV EBI the structural intervention is targeting, delivery setting, the patient or
305 provider population the implementation strategy or adjunctive intervention is targeting, and
306 implementation and recipient/patient-level outcomes. We will describe implementation strategy
307 and adjunctive intervention specification by mean specification rating. We will also tabulate the
308 number of studies addressing health disparities and/or health equity. We will tabulate the number
309 of structural interventions that, themselves, are implementation strategies and/or adjunctive
310 interventions. Due to the large amount of data potentially analyzed, we will use NLP to
311 thematically analyze strategies and adjunctive interventions to provide narrative description of
312 the types of strategies and adjunctive interventions identified across papers (54).

313 *Dissemination*

314 We will disseminate the results of this systematic review via two primary papers: one focused
315 on determinants of structural interventions for HIV EBIs and one focused on implementation
316 strategies and adjunctive interventions for HIV EBIs. We will produce additional qualitative
317 manuscripts examining determinants, implementation strategies, and adjunctive interventions

318 with greater nuance and depth for specific priority populations (e.g., transgender women) or
319 specific types of structural interventions (e.g., structural interventions targeting patient access).
320 We will share out results at research conferences. Finally, we will incorporate the results into a
321 literature review dashboard (<https://hivimpisci.northwestern.edu/dashboard/>) our team has created
322 out of previous systematic reviews. This dashboard will provide a high-level visualization of
323 determinants, implementation strategies, and adjunctive interventions by CFIR, ERIC, the TDF
324 and COM-B, as well as stratified by HIV EBI, structural intervention type, recipient/patient
325 population, provider role(s), delivery setting, geographic region of implementation, and
326 publication year. The dashboard is meant to serve researchers in exploring what has already been
327 identified by prior research, to aid them in deciding the direction of future research, as well as to
328 assist them in quickly identifying literature to include in publications and grant submissions.
329 Further, the dashboard is meant to serve as a tool to implementation practitioners, who may seek
330 to understand what determinants have been identified in their particular delivery settings or the
331 population(s) they serve and to identify potential implementation strategies or adjunctive
332 interventions to implement in their own delivery settings.

333 *Timeline*

334 We have thus far completed the initial search and the NLP screening process. We are
335 currently conducting title and abstract review. Full text review and extraction will begin January
336 2025 with both analyses beginning June 2025 and running through June 2026. Dissemination
337 will occur in Fall 2025 through Fall 2026.

338 **Discussion**

339 Our systematic review aims to address the critical gap in understanding and targeting the
340 barriers and facilitators to implementing HIV structural interventions in the U.S and will provide
341 insights that are essential for guiding efforts to scale up HIV structural interventions.

342 Understanding these implementation determinants, implementation strategies, and adjunctive
343 interventions is crucial for reaching marginalized populations who continue to face disparities in
344 access to and engagement with HIV EBIs.

345 Social and economic determinants such as housing stability, transportation, and healthcare
346 access are critical factors influencing HIV outcomes, particularly for racially, sexually, and
347 gender minoritized groups, and those with co-occurring conditions including substance misuse,
348 serious mental illness, and other infectious diseases and chronic conditions which make
349 treatment engagement more challenging (4,6,19). The implementation strategies and adjunctive
350 interventions to be identified in this review can inform future policy and program development.
351 For example, strategies that leverage digital health technologies, patient transportation and
352 housing, and adaptation of existing EBIs could address systemic barriers such as geographic,
353 financial, and social/linguistic constraints.

354 **Conclusion**

355 By providing a comprehensive analysis of the implementation determinants, implementation
356 strategies, and adjunctive interventions for HIV structural interventions, our review will identify
357 existing gaps in the literature and provide researchers with an understanding of the needs of the
358 field. These findings hold the potential to significantly advance the goals of the Ending the HIV
359 Epidemic initiative, particularly by addressing the complex needs of populations that have
360 historically been left behind in the fight against HIV.

361 **List of abbreviations**

362 CFIR: The Consolidated Framework for Implementation Research

363 EBI: Evidence based intervention

364 ERIC: Expert Recommendations for Implementation Change

365 GBMSM: Gay, bisexual, and other men who have sex with men

366 IS: Implementation science

367 NLP: Natural language processing

368 PrEP: Pre-exposure prophylaxis

369 PRISMA: Preferred reporting items for systematic reviews and meta-analyses

370 SDOH: Social and structural determinants of health

371 TDF: Theoretical Domains Framework

372 **Declarations**

373 Ethics approval and consent to participate: Not applicable.

374 Consent for publication: Not applicable

375 Availability of data and materials: The datasets used and/or analysed during the current study are
376 available from the corresponding author on reasonable request.

377 Competing interests: The authors declare that they have no competing interests.

378 Funding: This manuscript is funded by the National Institute for Mental Health, the National
379 Institute on Drugs Abuse, and the National Institute of Allergy and Infectious Diseases

380 (R24MH134305; PI: Mustanski and Benbow). The content is solely the responsibility of the

381 authors and does not necessarily represent the official views of the National Institutes of Health.

382 The sponsor had no involvement in the conduct of the research or the preparation of the article.

383 The sponsor had no involvement in the conduct of the research or the preparation of the protocol.

384 Author's Contributions: az, VAD, SC, MP, and RP contributed to the writing of the manuscript.

385 az, MH, NB, and BM contributed to the design. All authors reviewed the manuscript.

386 Acknowledgments: The authors would like to thank James Merle who assisted us in designing
387 the NLP screening strategy. The authors would also like to thank Corinne Miller who provided
388 consultation on the search strategy.

389

Table 1. Information to be extracted from articles included in the review	
Item	Definition/Explanation
Article Title	--
Publication Year	--
First Author's Name	--
Journal Name	--
Geographic Setting	Northeast, West, Midwest, South, U.S. colony, nationwide, simulation, unspecified, or other
Inner Setting ¹ Verbatim	Where the intervention is being delivered (e.g., HIV clinic, mobile testing unit)
Inner Setting Category	Specialized HIV Clinic, Substance Use Treatment Facility, Non-Specialized Private Clinic or Hospital, Community Health Centers, Pharmacy, Dental Clinic, Hospital System, Community Organization, Church, Prison/Jail, Emergency Department, Labor Unit/Department, Community Level, Legislative Bodies
Unit(s) of Analysis	Patients, providers, policy, non-primary data
Patient Population	If applicable; Who the paper identifies as their patient population
CDC Priority Population	Cisgender, gay and bisexual Men, African Americans, persons who use drugs, Latines, transgender individuals, cisgender women, adolescents (13-25)
Provider Role Verbatim	If applicable; Which role the paper identifies as delivering the intervention (e.g., HIV tester)
Provider Role Category	If applicable; HIV Tester, Physician, Pharmacist, Nurse, Laboratory Personnel, Community Health Worker, Program Leadership/Administration, Administrative Assistant, Policymaker, Peer Navigator, Case Manager, Business Owner, Other
Higher Level Unit of Analysis	If applicable (e.g., Policymakers, Public Health Department, Nonprofit Organization, Private Entities, Community)
HIV Evidence-Based Intervention	PrEP, HIV testing/diagnosis, Linkage to HIV Care, HIV Treatment, nPEP ² , or other intervention
Data Type	Qualitative, Quantitative, Mixed/Multi-Method, Simulation, N/A or Not Reported, and Other
Data Collection Method	Electronic Health/Medical Record, Survey, Surveillance, Participant Observation, Interview, Focus Group, Administrative Data, Policy Analysis, Document Review, Simulation, or Other
Study Design	Between-Site; Within- and Between-Site; Non-Experimental; Configurational Comparative Methods; Simulation Study; Other
Implementation Variables Studied	Determinants Only, Strategies Only, Both Strategies and Determinants

Implementation Outcome	Appropriateness, Adoption, Acceptability, Feasibility, Cost, Penetration, Sustainability, Other
Implementation Outcome Definition	How do the authors operationalize the implementation outcome
Structural Intervention Type	Access, Policy/Procedure, Mass Media, Physical Structure, Capacity-Building, Community Mobilization, Social Determinants of Health Intervention, Other
Structural Intervention Outcome	Access, Stigma Reduction, Housing, Food Stability, Poverty Alleviation, Use of Sterilized Syringes, Equity, Other

390 ¹ Inner setting is a domain of CFIR, which refers to the setting in which an intervention is
391 delivered.

392 ² nPEP refers to nonoccupational post-exposure prophylaxis, an oral pill taken within 72 hours of
393 exposure to HIV, which, if taken as prescribed, can prevent HIV infection.
394

395

396

397

398 **References**

399 1. Sullivan PS, Satcher Johnson A, Pembleton ES, Stephenson R, Justice AC, Althoff KN, et al.
400 Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses. *The*
401 *Lancet*. 2021 Mar 20;397(10279):1095–106.

402 2. Menza TW, Hixson LK, Lipira L, Drach L. Social Determinants of Health and Care
403 Outcomes Among People With HIV in the United States. *Open Forum Infect Dis*. 2021;8(7).

404 3. World Health Organization. A conceptual framework for action on the social determinants of
405 health [Internet]. 2010. (Debates, Policy, & Practice, Case Studies). Report No.: 2. Available
406 from:

407 https://iris.who.int/bitstream/handle/10665/44489/9789241500852_eng.pdf?sequence=1

408 4. The White House. National HIV/AIDS Strategy for the United States 2022–2025. 2022;
409 Available from: [https://www.whitehouse.gov/wp-content/uploads/2021/11/National-HIV-](https://www.whitehouse.gov/wp-content/uploads/2021/11/National-HIV-AIDS-Strategy.pdf)
410 [AIDS-Strategy.pdf](https://www.whitehouse.gov/wp-content/uploads/2021/11/National-HIV-AIDS-Strategy.pdf)

- 411 5. Centers for Disease Control and Prevention. Diagnoses, deaths, and prevalence of HIV in the
412 United States and 6 territories and freely associated states, 2022 [Internet]. 2024 [cited 2024
413 Oct 18]. (HIV Surveillance Report). Available from: [http://www.cdc.gov/hiv-data/nhss/hiv-](http://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html)
414 [diagnoses-deaths-prevalence.html](http://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html).
- 415 6. Dasgupta S, McManus T, Tie Y, Lin CYC, Yuan X, Sharpe JD, et al. Comparison of
416 Demographic Characteristics and Social Determinants of Health Between Adults With
417 Diagnosed HIV and All Adults in the U.S. *AJPM Focus*. 2023 Sep 1;2(3):100115.
- 418 7. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir
419 for HIV Prevention in Cisgender Men and Transgender Women. *N Engl J Med*. 2021 Aug
420 12;385(7):595–608.
- 421 8. Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, et al.
422 Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate
423 for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised,
424 double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. *Lancet Lond Engl*.
425 2020;396:239–54.
- 426 9. Jourdain H, de Gage SB, Desplas D, Dray-Spira R. Real-world effectiveness of pre-exposure
427 prophylaxis in men at high risk of HIV infection in France: a nested case-control study.
428 *Lancet Public Health*. 2022 Jun;7(6):e529–36.
- 429 10. Bonacci RA, Smith DK, Ojikutu BO. Toward Greater Pre-exposure Prophylaxis Equity:
430 Increasing Provision and Uptake for Black and Hispanic/Latino Individuals in the U.S. *Am J*
431 *Prev Med*. 2021 Nov;61(5 Suppl 1):S60.
- 432 11. Harawa NT, Tan D, Leibowitz AA. Disparities In Uptake Of HIV Pre-exposure Prophylaxis
433 Among California Medicaid Recipients. *Health Aff (Millwood)*. 2022 Mar;41(3):360–7.

- 434 12. Baugher A, Trujillo L, Kanny D, Freeman J, Hickey T, Sionean C, et al. Racial, Ethnic, and
435 Gender Disparities in Awareness of Preexposure Prophylaxis Among HIV-Negative
436 Heterosexually Active Adults at Increased Risk for HIV Infection — 23 Urban Areas, United
437 States, 2019 [Internet]. 2021 [cited 2024 Oct 18]. (MMWR Morb Mortal Wkly Rep). Report
438 No.: 70. Available from: <http://dx.doi.org/10.15585/mmwr.mm7047a3>
- 439 13. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al.
440 Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med*. 2011 Aug
441 11;365(6):493–505.
- 442 14. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al.
443 Antiretroviral Therapy for the Prevention of HIV-1 Transmission. *N Engl J Med*. 2016 Sep
444 1;375(9):830–9.
- 445 15. Cohen MS, Dye C, Fraser C, Miller WC, Powers KA, Williams BG. HIV Treatment as
446 Prevention: Debate and Commentary—Will Early Infection Compromise Treatment-as-
447 Prevention Strategies? *PLoS Med*. 2012 Jul 10;9(7):e1001232.
- 448 16. Delva W, Wilson DP, Abu-Raddad L, Gorgens M, Wilson D, Hallett TB, et al. HIV
449 Treatment as Prevention: Principles of Good HIV Epidemiology Modelling for Public Health
450 Decision-Making in All Modes of Prevention and Evaluation. *PLoS Med*. 2012 Jul
451 10;9(7):e1001239.
- 452 17. LeMessurier J, Traversy G, Varsaneux O, Weekes M, Avey MT, Niragira O, et al. Risk of
453 sexual transmission of human immunodeficiency virus with antiretroviral therapy,
454 suppressed viral load and condom use: a systematic review. *Can Med Assoc J*. 2018 Nov
455 19;190(46):E1350–60.
- 456 18. Holmes CB, Hallett TB, Walensky RP, Bärnighausen T, Pillay Y, Cohen MS. Effectiveness
457 and Cost-Effectiveness of Treatment as Prevention for HIV. In: Holmes KK, Bertozzi S,

- 458 Bloom BR, Jha P, editors. Major Infectious Diseases [Internet]. 3rd ed. Washington (DC):
459 The International Bank for Reconstruction and Development / The World Bank; 2017 [cited
460 2024 Oct 18]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK525180/>
- 461 19. Wood BR, Kassaye SG, Gerstoft J. Long-acting cabotegravir/rilpivirine for HIV-1 treatment:
462 real-world evaluation of barriers to implementation. *AIDS*. 2023 Mar 15;37(4):689–91.
- 463 20. Centers for Disease Control and Prevention. Ending the HIV Epidemic in the US (EHE).
464 2024 [cited 2024 Oct 18]. Ending the HIV Epidemic in the US Goals. Available from:
465 <https://www.cdc.gov/ehe/php/about/goals.html>
- 466 21. Greenwood G, Gaist P, Namkung A, Rausch D. Methodological and Measurement Advances
467 in Social Determinants of HIV: View from NIH. *AIDS Behav*. 2021 Mar 29;25(Suppl
468 2):127.
- 469 22. Adimora AA, Auerbach JD. Structural Interventions for HIV Prevention in the United States.
470 *JAIDS*. 2010 Dec 15;55(Supplement 2):S132–5.
- 471 23. Rubin R. It Takes an Average of 17 Years for Evidence to Change Practice-the Burgeoning
472 Field of Implementation Science Seeks to Speed Things Up. *JAMA*. 2023 Apr
473 25;329(16):1333–6.
- 474 24. Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated Consolidated
475 Framework for Implementation Research based on user feedback. *Implement Sci*.
476 2022;17(1):1–16.
- 477 25. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering
478 implementation of health services research findings into practice: a consolidated framework
479 for advancing implementation science. *Implement Sci*. 2009;4(1):1–15.

- 480 26. Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, et al. Outcomes for
481 Implementation Research: Conceptual Distinctions, Measurement Challenges, and Research
482 Agenda. *Adm Policy Ment Health*. 2011;38(2):65–76.
- 483 27. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion
484 interventions: the RE-AIM framework. *Am J Public Health*. 1999 Sep;89(9):1322–7.
- 485 28. Smith JD, Li DH, Merle JL, Keiser B, Mustanski B, Benbow ND. Adjunctive interventions:
486 change methods directed at recipients that support uptake and use of health innovations.
487 *Implement Sci*. 2024 Feb 8;19(1):10.
- 488 29. Fauci AS. Ending the HIV/AIDS Pandemic: Research and Implementation. *JAIDS*.
489 2013;62:55.
- 490 30. Hogg RS. Understanding the HIV care continuum. *Lancet HIV*. 2018 Jun 1;5(6):e269–70.
- 491 31. McNairy ML, El-Sadr WM. A Paradigm Shift: Focus on the HIV Prevention Continuum.
492 *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2014 Jul 1;59(Suppl 1):S12.
- 493 32. Centers for Disease Control and Prevention. Compendium of Evidence-Based Interventions
494 and Best Practices for HIV Prevention. 2022 [cited 2024 Oct 18]. Structural Interventions
495 (SI). Available from:
496 <https://www.cdc.gov/hiv/research/interventionresearch/compendium/si/index.html#:~:text=The%20Structural%20Interventions%20Chapter%20identifies,individual%20risk%20and%20protective%20behaviors>.
497
498
- 499 33. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation Hybrid
500 Designs: Combining Elements of Clinical Effectiveness and Implementation Research to
501 Enhance Public Health Impact. *Med Care*. 2012 Mar;50(3):217.

- 502 34. R Core Team. R: A language and environment for statistical computing [Internet]. Vienna,
503 Austria: R Foundation for Statistical Computing; 2021. Available from: [https://www.R-](https://www.R-project.org/)
504 [project.org/](https://www.R-project.org/)
- 505 35. Benoit K, Watanabe K. quanteda: Quantitative Analysis of Textual Data [Internet]. Available
506 from: <https://quanteda.io/>
- 507 36. Hornik K, Buchta C, Hothorn T, Karatzoglou A, Meyer D, Zeileis A. RWeka [Internet].
508 2023. Available from: <https://cran.r-project.org/web/packages/RWeka/index.html>
- 509 37. Wickham H, RStudio. tidyverse: Easily Install and Load the “Tidyverse” [Internet]. 2023.
510 Available from: <https://cran.r-project.org/web/packages/tidyverse/index.html>
- 511 38. De Quieroz G, Fay C, Hvitfeldt E, Keyes O, Mastny T, Erickson J, et al. tidytext: Text
512 Mining using “dplyr”, “ggplot2”, and Other Tidy Tools [Internet]. 2024. Available from:
513 <https://cran.r-project.org/web/packages/tidytext/index.html>
- 514 39. Robinson D, Hayes A, Couch S, Posit Software P, et al. broom: Convert Statistical Objects
515 into Tidy Tibbles [Internet]. 2024. Available from: [https://cran.r-](https://cran.r-project.org/web/packages/broom/index.html)
516 [project.org/web/packages/broom/index.html](https://cran.r-project.org/web/packages/broom/index.html)
- 517 40. Wickham H, Hester J, Francois R, Bryan J, Bearrows S, Posit Software P, et al. readr: Read
518 Rectangular Text Data [Internet]. 2024. Available from: [https://cran.r-](https://cran.r-project.org/web/packages/readr/index.html)
519 [project.org/web/packages/readr/index.html](https://cran.r-project.org/web/packages/readr/index.html)
- 520 41. Wickham H, Posit Software P. stringr: Simple, Consistent Wrappers for Common String
521 Operations [Internet]. 2023. Available from: [https://cran.r-](https://cran.r-project.org/web/packages/stringr/index.html)
522 [project.org/web/packages/stringr/index.html](https://cran.r-project.org/web/packages/stringr/index.html)
- 523 42. Bache S, Wickham H, Henry L, RStudio. magrittr: A Forward-Pipe Operator for R
524 [Internet]. 2022. Available from: <https://cran.r-project.org/web/packages/magrittr/index.html>

- 525 43. Veritas Health Innovation. Covidence Systematic Review Software [Internet]. Melbourne,
526 Australia; Available from: <https://support.covidence.org/help/how-can-i-cite-covidence>
- 527 44. Brown CH, Curran G, Palinkas LA, Aarons GA, Wells KB, Jones L, et al. An Overview of
528 Research and Evaluation Designs for Dissemination and Implementation. *Annu Rev Public*
529 *Health*. 2017 Mar 20;38:1.
- 530 45. Sipe TA, Barham TL, Johnson W, Joseph H, Tungol-Ashmon ML, O’Leary A. Structural
531 Interventions in HIV Prevention: A Taxonomy and Descriptive Systematic Review. *AIDS*
532 *Behav*. 2017 Dec;21(12):3366.
- 533 46. Verbi Software. MaxQDA 2022 [computer software] [Internet]. Berlin, Germany: VERBI
534 Software; Available from: maxqda.com
- 535 47. Damschroder LJ, Reardon CM, Opra Widerquist MA, Lowery J. Conceptualizing outcomes
536 for use with the Consolidated Framework for Implementation Research (CFIR): the CFIR
537 Outcomes Addendum. *Implement Sci*. 2022 Jan 22;17(1):7.
- 538 48. Skolarus TA, Lehmann T, Tabak RG, Harris J, Lecy J, Sales AE. Assessing citation
539 networks for dissemination and implementation research frameworks. *Implement Sci*. 2017
540 Jul 28;12(1):97.
- 541 49. Kirk MA, Kelley C, Yankey N, Birken SA, Abadie B, Damschroder L. A systematic review
542 of the use of the Consolidated Framework for Implementation Research. *Implement Sci*.
543 2016 May 17;11(1):72.
- 544 50. Powell BJ, Waltz TJ, Chinman MJ, Damschroder LJ, Smith JL, Matthieu MM, et al. A
545 refined compilation of implementation strategies: results from the Expert Recommendations
546 for Implementing Change (ERIC) project. *Implement Sci*. 2015 Feb 12;10(1):21.
- 547 51. Proctor EK, Powell BJ, McMillen JC. Implementation strategies: recommendations for
548 specifying and reporting. *Implement Sci*. 2013 Dec 1;8(1):139.

- 549 52. Atkins L, Francis J, Islam R, O'Connor D, Patey A, Ivers N, et al. A guide to using the
550 Theoretical Domains Framework of behaviour change to investigate implementation
551 problems. *Implement Sci.* 2017 Jun 21;12(1):77.
- 552 53. Michie S, van Stralen MM, West R. The behaviour change wheel: A new method for
553 characterising and designing behaviour change interventions. *Implement Sci.* 2011 Apr
554 23;6(1):42.
- 555 54. Guetterman TC, Chang T, DeJonckheere M, Basu T, Scruggs E, Vydiswaran VV.
556 Augmenting Qualitative Text Analysis with Natural Language Processing: Methodological
557 Study. *J Med Internet Res.* 2018 Jun 29;20(6):e231.
- 558